Plug & Play Upstream Development Service
Get straight to the point with our proprietary CHOZN® platform
Get straight to the point with our proprietary CHOZN® platform
Biopharm Process Development
From Cell Line to Process Development
Over 32 years of biomanufacturing experience demonstrated through more than 250 projects including:
Our goal is to enable our clients to reduce the time required to develop and produce cGMP biomolecules for clinical trials, through:
- Developing robust and scalable manufacturing processes
- Using the latest processing platforms and technologies
- Responsive, experienced scientists and project management
Biopharm Process Development Services include:
- Cell line development
- Clone selection
- Media & feed screening
- Upstream process development
- Master cell bank establishment
- Downstream process development
- Formulation development
- Analytical methods development & optimization
- Analytical process development support
- Biosimilars comparability analytical programs
Leverage our experience with these cell lines, expression platforms, and development activities
| CHO* Host | Expression | Molecule Type | M & F Screening | Process Development | Production Scale |
|---|---|---|---|---|---|
| CHOZN® | CHOZN® | Monoclonal antibody | ✓ | ✓ |
20L-2000L |
| S | DHFR | Recombinant Protein | ✓ | ✓ | 250L |
| DHFR | Fc-Fusion | ✓ | ✓ | 250L – 1,250L | |
| GS | Monoclonal antibody | ✓ | ✓ | 250L – 1,250L | |
| Catalent | Monoclonal antibody | ✓ | ✓ | 200L | |
| DUKX | DHFR | Recombinant Protein | ✓ | ✓ variant purification |
250L (perfusion) |
| DHFR | Monoclonal antibody | ✓ | ✓ | 1,250L | |
| DG44 | DHFR | Fc-Fusion | ✓ | 250L (perfusion) | |
| Biowa | Monoclonal antibody | ✓ | ✓ | 250L – 1,250L | |
| CHEF 1 | Monoclonal antibody | ✓ | |||
| K1/K1- SV |
DHFR | Fc-Fusion | ✓ | 3L (perfusion) | |
| GS | Monoclonal antibody | ✓ | ✓ | 20L – 2,000L | |
| M | Selexis | Monoclonal antibody | ✓ | ✓ | 20L – 2,000L |
| Horizon | GS | Monoclonal antibody | ✓ | 200L – 2,000L |
| Host | Molecule Type | M & F Screening | Process Development | Production Scale |
|---|---|---|---|---|
| Hybridoma | Monoclonal antibody | ✓ |
150L perfusion |
|
| NSO | Monoclonal antibody | ✓ | ✓ |
20L |
|
SP2/0 |
Monoclonal antibody | ✓ | ✓ | 200L |
Accelerate Identification of High-producing Cell Lines
Learn from Research BDS Scientist Lucie Grindes, BioReliance® End-to-End Solutions, about our mini-pool approach and how we can begin process development in parallel with cell line development.Featured Resources
 The key to this success is to make the right decisions at the right time. In this guidebook, our experts share some key considerations to help biopharmaceutical companies successfully advance a molecule from the laboratory to the clinic as quickly as possible without sacrificing product quality, process efficiency, or patient safety. Read Now |
|
 Learn how our approach to mini pools allows us to deliver high-producing clones in an accelerated timeline, saving up to 3 months. In addition, we are able to begin process development in parallel with cell line development for clients with very challenging timelines. Read Now |
|
 Webinars: |
|
 Brochure: Your Partner To Speed From DNA To Market |
 Brochure: Plug & Play Upstream Development ServiceA service exactly tailored to small-sized biotechs and start-ups, needing to balance cost and speed to clinic while getting it right the first time. Download Brochure |
Article